The anti-Covid vaccine from the American Novavax has shown an overall effectiveness of 90.4% in a phase 3 study that involved almost 30 thousand participants in 119 centers between the US and Mexico. The effectiveness was 100% in preventing moderate and severe forms of the disease, the company reports.
The product, Novavax points out, also works against Sars-CoV-2 variants. In particular, it is 93% effective against so-called variants of concern (Voc) and against variants of interest (Voi) prevalently circulating, and 100% against variants not considered Voc / Voi.
Protection in high-risk populations is 91%, the group adds. All hospitalizations / deaths occurred in the placebo group.
Novavax’s is a protein-based vaccine – as described by the European Drug Agency EMA, which has already started the cyclic review on the product – which contains tiny particles obtained from a laboratory-made version of the Spike protein present on the surface of the coronavirus. pandemic. It also uses an adjuvant, a substance that helps strengthen immune responses stimulated by the injection-shield.
The results of the ‘Prevent-19’ study “reinforce” the evidence “that NVX-CoV2373 is extremely effective and offers comprehensive protection against both moderate and severe Covid-19 infection,” said Stanley C. Erck, president and CEO of Novavax.
The trial “confirms that NVX-CoV2373 offers a reassuring safety and tolerability profile – says Gregory M. Glenn, President of Research & Development, Novavax – These data show high levels of efficacy and reaffirm the vaccine’s ability to prevent Covid-19 in a phase in which a genetic evolution of the virus is underway. Our vaccine will contribute in a fundamental way to the solution of the Covid emergency “, is convinced Glenn who thanks” the participants in the study, the operators who made it possible as well as ours supporters, including the US government. “